![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The partnership between NFL Biosciences and Diverchim will involve manufacturing the active ingredient for NFL-101 for its use in additional clinical trials beyond the current CESTO II study (Phase II/III).
Lead Product(s): Tobacco Leaf Protein,Nicotine
Therapeutic Area: Psychiatry/Psychology Product Name: NFL-101
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: NFL Biosciences
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2021